Alfa Cytology - Cancer Drug R&D Services

Melanoma

Inquiry

Melanoma is an aggressive malignancy with high metastatic risk that can affect the skin, mucosa, eye, and central nervous system. Alfa Cytology is a global leader in cancer research. With our extensive experience and advanced platforms, our talented scientists provide one-stop solutions for melanoma animal model development, efficacy evaluation, skin orthotopic model validation, lung/brain/liver metastasis research, tumor immunology testing, target expression validation, pathology testing, molecular mechanism testing, and PK/PD, based on client candidate drugs, molecular subtyping, treatment scenario, cell line characteristics, organ metastasis direction, immune system requirements, and R&D stages. We also provides zebrafish experimental services and cell-based experimental services, covering diverse research needs from in vitro to in vivo and from high-throughput screening to mechanism validation.

Introduction to Melanoma

Melanoma is a malignant tumor originating from melanocytes that can occur in the skin, mucosa, eye, and central nervous system, and is one of the fastest-growing malignancies worldwide. Melanoma is highly heterogeneous, with significant differences in molecular subtype, driver gene, metastatic organ preference, and immune microenvironment. Clinically, melanoma is commonly classified based on driver genes such as BRAF, NRAS, and NF1. BRAF V600-mutant melanoma is primarily treated with BRAF/MEK inhibitors and immune checkpoint inhibitors; NRAS/NF1 background melanoma relies more on MEK/ERK/PI3K combination strategies and immunotherapy; uveal melanoma is characterized by GNAQ/GNA11 mutations and liver metastasis, and its treatment strategy differs markedly from cutaneous melanoma. Common metastatic organs in melanoma include lymph nodes, lung, brain, liver, and bone. Among these, brain metastasis and liver metastasis are high-priority scenarios in translational research and require dedicated modeling in drug evaluation. Melanoma is one of the most common solid tumor directions in immunotherapy research, with PD-1/PD-L1, CTLA-4, STING, oncolytic virus, and TCE strategies widely applied in this cancer type.

Fig. 1 Melanoma driver genes and pathways.Fig. 1 Mutated driver genes and downstream signal pathways in melanoma. (Guo W, et al.; 2021)

Based on the continuous evolution of technology, some companies are already developing specific pipelines related to potential therapies for melanoma.

Targets Therapeutics Company Molecule Type Phase
LAG-3 Favezelimab + pembrolizumab (MK-4280a) Merck Monoclonal antibody
HER3 IgG1 Patritumab deruxtecan (MK-1022) Merck Antibody-drug conjugate
/ Autogene cevumeran Genentech mRNA Vaccine
MEK Cobimetinib Genentech Small molecule

Our Services

Alfa Cytology has established a comprehensive solution platform for melanoma animal experimental research, built around BRAF/NRAS/NF1 molecular stratification, skin orthotopic microenvironment, local invasion and lymphatic dissemination, organ-specific metastasis (lung/brain/liver), immunotherapy, humanized immunotherapy, BRAF/MEK resistance, and postoperative relapse/MRD scenarios. Leveraging this integrated platform, we provide end-to-end services covering the full melanoma drug development workflow.

Preclinical Efficacy Studies

Melanoma drug development requires model selection based on BRAF/NRAS/NF1 molecular stratification, skin orthotopic microenvironment, local invasion and lymphatic dissemination, organ-specific metastasis (lung/brain/liver), immune requirements, and postoperative relapse/MRD scenarios. Alfa Cytology provides integrated animal study solutions, from cell line selection to model validation, for BRAF/MEK inhibitors, NRAS/NF1 pathway agents, ADCs, bispecifics, TCEs, CAR-T/NK, PD-1/PD-L1, CTLA-4, STING, oncolytic virus, radiotherapy combination, and postoperative relapse programs.

Melanoma Mechanism Research

For melanoma studies, experimental design typically needs to address molecular stratification, skin microenvironment, local invasion, organ-specific metastasis, immune microenvironment, and drug resistance simultaneously. Alfa Cytology provides model development, dosing intervention, pathology testing, immunology testing, protein testing, and RNA testing services, covering BRAF V600, NRAS, NF1, MAPK pathway, BRAF/MEK resistance, withdrawal rechallenge, lung/brain/liver metastasis, uveal melanoma GNAQ/GNA11, TME remodeling, and MRD clearance.

Clinical Relevance Studies

When programs advance to skin orthotopic microenvironment, lung metastasis, brain metastasis, uveal melanoma liver metastasis, immunotherapy, humanized immunotherapy, BRAF/MEK resistance, or postoperative relapse/MRD stages, Alfa Cytology can further configure skin orthotopic models, experimental lung metastasis models, brain metastasis models, uveal melanoma liver metastasis models, syngeneic immunocompetent models (B16-F10/YUMM1.7/YUMMER1.7), humanized immune models, or post-resection relapse models to help clients generate evidence more aligned with clinical scenarios.

In Vitro and In Vivo Layered Validation

Animal studies can address whether a candidate inhibits tumor growth, local invasion, lymph node metastasis, lung/brain/liver metastasis, or postoperative relapse; zebrafish platforms provide high-throughput in vivo screening covering tumor proliferation, skin orthotopic colonization, local invasion, lymphatic dissemination, organ-specific metastatic invasion, angiogenesis, immune co-culture, and drug toxicity; cell-based experiments validate proliferation, apoptosis, migration and invasion, BRAF/NRAS/NF1 pathways, pERK/pMEK, drug internalization, resistance mechanisms, and immune killing.

Candidate Screening

Early screening typically requires rapid assessment of whether a candidate demonstrates in vivo antitumor signals. Alfa Cytology conducts TGI, RTV, PK/PD, pERK, pMEK, and target evaluations using molecularly matched subcutaneous CDX models, providing data to support dose selection, dosing frequency, and candidate prioritization.

Molecular Mechanism Studies

Depending on program needs, we offer IHC, IF, flow cytometry, ELISA, Western blot, qPCR, RNA-seq, pERK, pMEK, BRAF/NRAS/NF1 status, PD-L1, CD8/Treg, myeloid cell profiling, cytokines, brain tissue exposure, liver tissue exposure, and immune reconstitution testing.

Supported R&D Programs

R&D Project Cell Lines Host System Preferred Model Key Endpoints
BRAF mutation early efficacy screening A375, SK-MEL-28, Colo829, WM793 BALB/c nude, NOD-SCID, NSG BRAF-mutant subcutaneous CDX TGI, RTV, terminal tumor weight, pERK, pMEK, Ki67, apoptosis, PK/PD.
BRAF/MEK resistance and withdrawal rechallenge A375-resistant lines, Colo829-resistant lines, long-term dosing-induced models BALB/c nude, NOD-SCID, NSG BRAF CDX with long-term dosing or resistant derivatives, orthotopic confirmation when needed Time to relapse, pERK recovery, bypass pathway, RTV regrowth, resistance markers.
NRAS/NF1 background programs SK-MEL-2, SK-MEL-30, WM1366 BALB/c nude, NOD-SCID, NSG Molecularly matched subcutaneous CDX, orthotopic or metastasis model for confirmation when needed TGI, pERK, pAKT, MEK/ERK/PI3K pathway, cell cycle, apoptosis.
High-invasion / local invasion research A2058, WM266-4, A375-luc BALB/c nude, NOD-SCID, NSG High-invasion CDX, skin orthotopic model for confirmation TGI, local invasion, EMT, MMP, local pathology, survival.
Skin local microenvironment and lymphatic dissemination A375-luc, A2058-luc, WM266-4-luc, B16-F10-luc, YUMM/YUMMER BALB/c nude, NOD-SCID, NSG; C57BL/6 immunocompetent mice Skin orthotopic model Orthotopic burden, local invasion, lymph node metastasis, IVIS, survival, immune infiltration.
Lung metastasis colonization research B16-F10-luc, A375-luc, A2058-luc C57BL/6 immunocompetent mice; NSG, NOD-SCID Tail vein experimental lung metastasis model Lung nodule count, lung weight, IVIS, lung histopathology, survival.
Orthotopic spontaneous lung metastasis / postoperative metastasis relapse B16-F10-luc, A2058-luc, YUMM/YUMMER C57BL/6 immunocompetent mice; NSG, NOD-SCID Skin orthotopic model with long-term observation or post-resection follow-up Orthotopic burden, post-resection relapse, lung metastasis, survival, time to relapse.
Brain metastasis and BBB scenario A2058-Br, A375-Br, B16-F10-Br, high-invasion brain metastasis derivatives BALB/c nude, NOD-SCID, NSG; C57BL/6 immunocompetent mice Left ventricle / carotid artery brain metastasis or intracranial inoculation model MRI, BLI, brain metastatic lesions, survival, neurobehavior, brain edema, brain tissue exposure.
Uveal melanoma liver metastasis OMM1, 92.1, Mel290, liver metastasis derivatives BALB/c nude, NOD-SCID, NSG Liver metastasis model, with intraocular orthotopic linkage when needed Liver nodule count, liver weight, IVIS, liver pathology, survival, GNAQ/GNA11-related pathway
Immune checkpoint / combination immunotherapy B16-F10, B16-F1, YUMM1.7, YUMMER1.7 C57BL/6 immunocompetent mice Syngeneic immunocompetent model, orthotopic preferred TGI/IVIS, CD8/Treg, myeloid cells, PD-L1, IFN-γ, Granzyme B, survival
STING / oncolytic virus / radiotherapy combination B16-F10-luc, YUMM1.7, YUMMER1.7 C57BL/6 immunocompetent mice Syngeneic subcutaneous or orthotopic model Orthotopic burden, immune infiltration, cytokines, necrosis, abscopal effect, survival.
TCE / CAR-T/NK / human immune-dependent therapies A375, SK-MEL-28, A2058, WM266-4 and others huPBMC or huHSC-reconstituted NSG/NOG mice Humanized immune model hCD45, hCD3, hCD8, hNK, T cell activation, cytokines, xGvHD/CRS risk.
Postoperative relapse / MRD clearance B16-F10-luc, YUMM/YUMMER, A2058-luc C57BL/6 immunocompetent mice; NSG, NOD-SCID Skin orthotopic model with post-resection relapse observation Local relapse, lung/brain metastasis, survival, MRD clearance, immune infiltration.

Comprehensive Test and Data Analysis Platform

For melanoma programs focused on molecular stratification, skin orthotopic microenvironment, and organ-specific metastasis evaluation, we configure TGI, RTV, terminal tumor weight, BLI, MRI, lung nodule count, brain metastatic burden, liver metastatic nodules, local invasion, lymph node metastasis, survival, pERK, pMEK, Ki67, cleaved caspase-3, PD-L1, CD8/Treg, myeloid cell profiling, and brain/liver tissue exposure, forming an integrated data chain linking molecular stratification, organ metastasis, and immune microenvironment.

Multimodal In Vivo Imaging

  • IVIS Spectrum photon bioluminescence quantification for skin orthotopic tumors, lung metastasis, and liver metastasis tracking
  • 7.0T small-animal high-field MRI for brain metastatic lesion and BBB penetration evaluation
  • micro-CT 3D reconstruction for bone metastasis and organ metastasis assessment

Pathology and IHC/IF Staining

  • BRAF / NRAS / NF1 / pERK / pMEK molecular stratification and pathway assessment
  • Ki67 / Cleaved-Caspase 3 proliferation and apoptosis index
  • mIF multiplex immunofluorescence for in situ target and melanoma TME quantification

TME Microenvironment and Immune Profiling

  • Melanoma TILs (CD4+ / CD8+ / Treg) infiltration analysis
  • TAM (M1 / M2) and MDSC suppressive subsets
  • Cytokine storm (IFN-γ / IL-6) CBA suspension array

Access Our Melanoma Model Library

Melanoma Cell Line Panel

Alfa Cytology's melanoma cell line panel covers five key areas, including BRAF/NRAS/NF1 molecular stratification, skin orthotopic microenvironment, organ-specific metastasis, resistance research, and immuno-oncology, enabling cell line selection and matching based on molecular stratification, organ metastasis direction, target expression, and immune system requirements.

BRAF Mutation-Related Cell Lines

  • A375: the most commonly used BRAF V600E model, suitable for BRAF inhibitors, MEK inhibitors, BRAF/MEK combination, PROTAC, and resistance research. A375-luc can be used for orthotopic or metastasis model escalation.
  • SK-MEL-28: a BRAF-mutant model suitable for MAPK pathway, BRAF/MEK combination, resistance mechanisms, and immune target expression research.
  • Colo829: suitable for targeted agents, resistance evolution, long-term dosing, and withdrawal rechallenge research.
  • WM793: suitable for BRAF mutation and early lesion-related research, and can be combined with A375 and SK-MEL-28 for different invasion and differentiation background validation.

NRAS/NF1 Background Cell Lines

  • SK-MEL-2: suitable for NRAS background, MEK/ERK pathway, PI3K bypass, and combination therapy research.
  • SK-MEL-30: suitable for NRAS background and non-BRAF stratified programs, including MEK, ERK, PI3K, CDK4/6, or combination therapy directions.
  • WM1366: suitable for NRAS/NF1-related mechanisms, MAPK reprogramming, resistance, and combination strategy research.

High-Invasion and Metastasis-Prone Cell Lines

  • A2058: suitable for high-invasion, high-migration, brain metastasis, and organ metastasis early-stage research. A2058-luc or brain metastasis derivatives can be used for orthotopic and brain metastasis models.
  • WM266-4: suitable for local invasion, metastatic capacity evaluation, and efficacy validation in high-invasion background.
  • A2058-Br, A375-Br, B16-F10-Br: brain metastasis derivatives suitable for brain metastasis, BBB penetration, intracranial efficacy, and brain microenvironment research.

Immuno-Oncology-Related Cell Lines

  • B16-F10: a classic C57BL/6 background melanoma model, fast-growing and highly lung metastatic, suitable for immunotherapy early screening, lung metastasis, postoperative relapse, and TME intervention research.
  • B16-F1: relatively lower metastatic capacity, can be used as an invasion control against B16-F10.
  • YUMM1.7: with well-defined genetic background, suitable for BRAF/PTEN-related mechanisms, immunotherapy, and TME research.
  • YUMMER1.7: more immunogenic, suitable for immune checkpoint, T cell infiltration, immune resistance, and combination therapy research.

Uveal Melanoma-Related Cell Lines

  • OMM1, 92.1, Mel290, and liver metastasis derivatives: suitable for uveal melanoma programs; liver metastasis models should be prioritized, focusing on GNAQ/GNA11, BAP1, and liver microenvironment.

Target Expression-Related Cell Lines

  • BRAF: A375, SK-MEL-28, Colo829, WM793.
  • NRAS/NF1: SK-MEL-2, SK-MEL-30, WM1366.
  • GNAQ/GNA11: OMM1, 92.1, Mel290.
  • ADC and bispecific programs should first confirm target antigen expression stability and re-verify in in vivo models.

Melanoma Animal Model Panel

Alfa Cytology provides end-to-end melanoma animal model development services, spanning model design, cell line selection, model construction, dosing intervention, efficacy evaluation, pathology, immunology, molecular mechanism testing, and PK/PD analysis. The models below represent our core capabilities across BRAF/NRAS/NF1 molecular stratification, skin orthotopic microenvironment, local invasion and lymphatic dissemination, lung/brain/liver organ-specific metastasis, immunotherapy, humanized immunotherapy, and BRAF/MEK resistance and postoperative relapse/MRD research. Each model can be customized to match your program's molecular subtype, treatment scenario, cell line characteristics, organ metastasis direction, immune system requirements, and R&D stage, from early screening to clinical relevance validation.

Subcutaneous Xenograft Model (CDX)

Subcutaneous CDX models typically involve inoculating human melanoma cells subcutaneously into immunodeficient mice, followed by randomization and dosing once tumors reach a predetermined volume. Commonly used hosts include BALB/c nude, NOD-SCID, and NSG mice.

  • BRAF-mutant subcutaneous CDX: A375, SK-MEL-28, Colo829, WM793
  • NRAS/NF1 background subcutaneous CDX: SK-MEL-2, SK-MEL-30, WM1366
  • High-invasion subcutaneous CDX: A2058, WM266-4, A375-luc

Model characteristics
A375, SK-MEL-28, Colo829, and WM793 are suitable for BRAF inhibitors, MEK inhibitors, BRAF/MEK combination, small molecules, PROTAC, ADC, and resistance early research. SK-MEL-2, SK-MEL-30, and WM1366 are suitable for MEK, ERK, PI3K, cell cycle, and combination therapy strategies. A2058 and WM266-4 are suitable for high-invasion, anti-metastasis early screening, and brain metastasis front-end evaluation. If the program focuses on brain metastasis or organ-specific dissemination, escalation to metastasis models is required. This model is not suitable for independently answering questions about skin orthotopic microenvironment, lymphatic dissemination, brain metastasis, lung metastasis, and immunotherapy.

Modeling and dosing timelines
Subcutaneous CDX typically reaches enrollment volume 1–3 weeks after inoculation, with randomization commonly performed at tumor volumes of approximately 80–150 mm3. The conventional treatment period is 2–4 weeks; for resistance, withdrawal rechallenge, long-term combination therapy, or maintenance therapy studies, this can be extended to 4–8 weeks. BRAF/MEK inhibitors are typically designed for daily oral dosing; antibodies and ADCs can be dosed weekly or every 2 weeks; combination therapy requires dosing sequence design based on pharmacokinetic and toxicity windows.

Detection endpoints

  • Basic efficacy layer: TGI, RTV, terminal tumor weight, body weight, general condition, progression-free time, and survival
  • MAPK pathway layer: pERK, pMEK, pAKT, BRAF/MEK target occupancy, pathway rebound, and resistance bypass
  • Cell fate layer: Ki67, cleaved caspase-3, TUNEL, cell cycle, and necrosis
  • PK/PD layer: Plasma drug concentration, tumor tissue concentration, target inhibition duration, intratumoral exposure, and exposure-efficacy relationship

Recommended positive controls
Vemurafenib can be designed at 25–75 mg/kg oral daily dosing; dabrafenib can be designed at 10–30 mg/kg oral daily dosing, with simultaneous detection of pERK decline and pathway rebound. Trametinib can be designed at 0.1–1 mg/kg oral daily dosing, and BRAF/MEK combination can serve as the core reference framework for BRAF-mutant programs. For non-BRAF background or high-invasion models, cytotoxic agents, MEK/ERK inhibitors, or other targeted combination references can be set according to program mechanism.

Skin Orthotopic Model

Human skin orthotopic models can use A375-luc, A2058-luc, or WM266-4-luc to establish local orthotopic tumors at skin-related sites. B16-F10-luc, YUMM1.7, and YUMMER1.7 can establish syngeneic orthotopic models in C57BL/6 background.

Model characteristics
A375-luc is more suitable for BRAF background and orthotopic efficacy validation; A2058-luc is more suitable for high-invasion and spontaneous metastasis front-end research; B16-F10-luc is more suitable for immunocompetent rapid metastasis research; YUMM/YUMMER is more suitable for immune mechanism and clear molecular background research. This model is suitable for observing local invasion, surrounding skin tissue reaction, spontaneous metastasis, and local treatment efficacy, and is also suitable for immunotherapy, TME remodeling, radiotherapy combination, and postoperative relapse research in syngeneic immunocompetent background. Orthotopic models have more complex procedures, greater inter-batch variability, and lower throughput, and are not suitable as a first-round rapid ranking platform for multiple candidates.

Modeling and dosing timelines
Skin orthotopic models typically form monitorable lesions 1–3 weeks after inoculation, depending on cell line, inoculation method, and animal background. Luc-labeled models can be longitudinally tracked via IVIS. The conventional treatment period is 2–6 weeks; if studying spontaneous metastasis, postoperative relapse, or immune resistance, observation can be extended. Postoperative relapse and MRD models typically perform resection or local treatment when orthotopic tumors reach approximately 80–150 mm3 or a predetermined burden, followed by relapse and metastasis follow-up.

Detection endpoints

  • Orthotopic burden layer: Orthotopic tumor volume, IVIS, local pathology, skin infiltration, necrosis, vascular invasion, and survival
  • Local metastasis layer: Lymph node metastasis, lung metastasis, local relapse, time to relapse, and spontaneous metastatic burden
  • Immune microenvironment layer: CD8, Treg, MDSC, macrophages, DC cells, PD-L1, IFN-γ, Granzyme B, and cytokines
  • Local treatment layer: Local drug concentration, intratumoral distribution, skin tissue reaction, radiotherapy damage, and local safety

Recommended positive controls
A375-luc orthotopic models can set dabrafenib + trametinib or vemurafenib + MEK inhibitor as BRAF mutation references. In B16-F10, YUMM1.7, or YUMMER1.7 orthotopic models, anti-PD-1, anti-CTLA-4, or PD-1/CTLA-4 combination references can be set, with antibody doses commonly at 100–200 μg/mouse intraperitoneally, twice weekly or once every 3 days, for 2–3 consecutive weeks. STING agonists, oncolytic viruses, local cytokines, or radiotherapy combinations can be set according to program mechanism, with simultaneous observation of local inflammation and systemic immune response.

Lung Metastasis Model

Lung metastasis models can use B16-F10-luc, A375-luc, or A2058-luc. Experimental lung metastasis is typically established by tail vein injection, while spontaneous lung metastasis can be established by long-term observation of skin orthotopic models or post-resection follow-up.

Model characteristics
Tail vein models primarily address lung colonization and do not fully represent the complete natural metastasis cascade. Spontaneous metastasis models are closer to the clinical process but have longer cycles and greater variability.

Modeling and dosing timelines
Experimental lung metastasis is typically observed for 2–6 weeks; spontaneous lung metastasis has a total cycle of typically 4–10 weeks, depending on orthotopic lesion growth rate and metastasis formation time.

Detection endpoints

Lung nodule count, lung weight, IVIS, lung tissue HE, metastatic area, Ki67, apoptosis, immune infiltration, and survival.

Recommended positive controls
BRAF-mutant models can reference BRAF/MEK inhibitors; syngeneic immune models can reference anti-PD-1, anti-CTLA-4, or combination immunotherapy; anti-metastasis programs can set targeted agents, cytotoxic agents, or local therapy references according to mechanism.

Brain Metastasis Model

Brain metastasis models can use A2058-Br, A375-Br, B16-F10-Br, or high-invasion brain metastasis derivatives. Modeling approaches include left ventricle injection, carotid artery injection, and intracranial inoculation. Left ventricle or carotid artery injection is more suitable for brain colonization and BBB crossing research, while intracranial inoculation is more suitable for intracranial efficacy and brain tissue exposure research.

Model characteristics
Brain metastasis models differ significantly from subcutaneous CDX. Intracranial efficacy requires combined analysis of BBB penetration, brain tissue exposure, and brain microenvironment, and cannot be directly inferred from subcutaneous tumor shrinkage.

Modeling and dosing timelines
Brain metastasis model are typically observed for 2–8 weeks. The treatment window needs to be set based on BLI, MRI, or neurological symptom changes, avoiding excessive tumor burden affecting endpoint assessment.

Detection endpoints

MRI, BLI, brain metastatic lesion count, brain edema, neurobehavior, survival, brain tissue HE, Ki67, apoptosis, BBB-related markers, and brain tissue drug concentration.

Recommended positive controls
BRAF-mutant brain metastasis programs can set dabrafenib/trametinib, encorafenib/binimetinib, or other clinical mapping strategies based on the model; immune-related brain metastasis programs can set PD-1/CTLA-4 references in appropriate immune models.

Uveal Melanoma Liver Metastasis Model

Uveal melanoma liver metastasis models can use OMM1, 92.1, Mel290, or liver metastasis derivatives. Modeling approaches include intrasplenic injection, portal vein-related modeling, intrahepatic inoculation, or intraocular orthotopic tracking of liver metastasis.

Model characteristics
This model is suitable for uveal melanoma liver metastasis and should not directly replace cutaneous melanoma lung metastasis or brain metastasis pathways.

Modeling and dosing timelines
Liver metastasis models are typically observed for 3–8 weeks. The specific cycle depends on cell line, inoculation method, and liver metastasis burden formation rate.

Detection endpoints

Liver metastatic nodule count, liver weight, IVIS, liver tissue HE, survival, GNAQ/GNA11-related pathway, intrahepatic immune microenvironment, and liver tissue drug concentration.

Recommended positive controls
Uveal melanoma programs can set MEK, PKC, HDAC, Tebentafusp-related clinical mapping, or liver local therapy references according to mechanism. Specific models need to be designed based on human target and immune system compatibility.

Syngeneic Subcutaneous Model

Syngeneic subcutaneous models commonly use B16-F10, B16-F1, YUMM1.7, or YUMMER1.7 in C57BL/6 mice. Enrollment occurs when tumor volume reaches approximately 50–100 mm3.

Model characteristics
This model retains an intact immune system and is suitable for immunotherapy early screening and TME mechanism validation. B16-F10 grows fast and has strong lung metastasis capacity, suitable for immunotherapy early screening, lung metastasis, postoperative relapse, and TME intervention research, but its immunotherapy window is relatively short, requiring control of enrollment burden and dosing timing in experimental design. B16-F1 has relatively lower metastatic capacity and can be used as an invasion control against B16-F10. YUMM1.7 has a well-defined genetic background, suitable for BRAF/PTEN-related mechanisms, immunotherapy, and TME research, with stronger molecular interpretability than B16-F10. YUMMER1.7 is typically more immunogenic, suitable for immune checkpoint, T cell infiltration, immune resistance, and combination therapy research.

Modeling and dosing timelines
Enrollment occurs when tumor volume reaches approximately 50–100 mm3, with a treatment period of typically 10–21 days. B16-F10 grows faster, so treatment should be initiated earlier; YUMM/YUMMER can provide a relatively longer immune observation window.

Detection endpoints

Tumor volume, TGI, body weight, survival, flow cytometry immune profiling, CD8/Treg, myeloid cells, cytokines, PD-L1, and IHC/IF.

Recommended positive controls
anti-PD-1, anti-PD-L1, anti-CTLA-4, or PD-1/CTLA-4 combination can serve as immune checkpoint references. STING, oncolytic virus, cytokines, and radiotherapy combination can be set according to mechanism.

Syngeneic Orthotopic Model

Syngeneic orthotopic models can use B16-F10-luc, YUMM1.7, or YUMMER1.7 to establish skin orthotopic tumors. This model combines skin local microenvironment and intact immune system.

Model characteristics
This model is suitable for immunotherapy, radiotherapy combination, local therapy, spontaneous metastasis, and relapse research, and also suitable for PD-1/CTLA-4, STING, oncolytic virus, local immune activation, radiotherapy combination, postoperative relapse, and TME remodeling research. This model retains an intact immune system and is suitable for immunotherapy, TME, local immunity, and metastasis research, but its limitation is that murine models differ from human melanoma in antigen expression, targets, and molecular background.

Modeling and dosing timelines
Skin orthotopic models typically form monitorable lesions 1–3 weeks after inoculation, and luc-labeled models can be longitudinally tracked via IVIS. The conventional treatment period is 2–6 weeks; if studying spontaneous metastasis, postoperative relapse, or immune resistance, observation can be extended.

Detection endpoints

Orthotopic tumor burden, IVIS, local invasion, lymph node metastasis, lung metastasis, survival, CD8/Treg, myeloid cell profile, cytokines, and spatial immune analysis.

Recommended positive controls
anti-PD-1, anti-PD-L1, anti-CTLA-4, or PD-1/CTLA-4 combination can serve as immune checkpoint references. STING, oncolytic virus, cytokines, local immune activation, and radiotherapy combination can be set according to mechanism.

huPBMC Model

The huPBMC model establishes a short-term human immune effector environment by infusing human peripheral blood mononuclear cells into immunodeficient mice, combined with human melanoma cell lines. Commonly used cell lines include A375, SK-MEL-28, A2058, and WM266-4.

Model characteristics
This model is suitable for TCE, CAR-T/NK, human cytokines, human immune checkpoints, ADC combination immunotherapy, and short-term human immune effector validation. This model has a long cycle, high cost, significant donor variability, and carries xGvHD or cytokine release risk; it is not recommended as a large-scale early screening model, but is more suitable as a key immune mechanism and translational validation platform.

Modeling and dosing timelines
A short-term human immune effector environment is established by infusing human peripheral blood mononuclear cells; modeling is relatively rapid, and primary endpoints should be completed within a controllable window.

Detection endpoints

hCD45, hCD3, hCD4, hCD8, hNK, T cell activation, tumor infiltration, IFN-γ, TNF-α, IL-6, Granzyme B, tumor burden, body weight, CRS, and xGvHD risk markers.

Recommended positive controls
anti-human PD-1, anti-human PD-L1, anti-human CTLA-4, or related combination strategies can serve as mechanistic references, with doses determined by antibody half-life, model window, and human immune reconstitution status. TCE, CAR-T, or CAR-NK programs should include target-positive, target-low/negative, effector cell controls, and empty vector/irrelevant TCE controls. Cell therapy doses are often designed on the order of 106–107 cells/mouse, determined by the cell product and safety window.

huHSC Model

The huHSC model reconstructs a relatively long-term human immune system via human hematopoietic stem cells, suitable for complex immune mechanisms, immune resistance, long-term treatment, and combination regimen validation.

Model characteristics
This model is suitable for complex immune mechanisms, immune resistance, long-term treatment, and combination regimen validation. This model has a long cycle, high cost, significant donor variability, and carries xGvHD or cytokine release risk; it is not recommended as a large-scale early screening model, but is more suitable as a key immune mechanism and translational validation platform.

Modeling and dosing timelines
A relatively long-term human immune system is reconstructed via human hematopoietic stem cells; the cycle is longer, suitable for long-cycle human immune reconstitution and complex combination regimen research.

Detection endpoints

Human immune reconstitution ratio, T/B/NK/myeloid cell spectrum, tumor infiltration, cytokines, human immune checkpoint expression, tumor burden, survival, and major organ pathology.

Recommended positive controls
anti-human PD-1, anti-human PD-L1, anti-human CTLA-4, or related combination strategies can serve as mechanistic references, with doses determined by antibody half-life, model window, and human immune reconstitution status. TCE, CAR-T, or CAR-NK programs should include target-positive, target-low/negative, effector cell controls, and empty vector/irrelevant TCE controls. Cell therapy doses are often designed on the order of 106–107 cells/mouse, determined by the cell product and safety window.

Postoperative Relapse and Minimal Residual Disease Model

Postoperative relapse and MRD models typically use skin orthotopic models as the base. First, measurable orthotopic tumor burden is established, followed by local resection, debulking, or local treatment.

Model characteristics
Resection is performed when orthotopic tumors reach approximately 80–150 mm3 or a predetermined burden, followed by observation of local relapse, lung metastasis, brain metastasis, or distant metastasis. Commonly used models include B16-F10-luc, YUMM/YUMMER, and A2058-luc. Preoperative therapy, postoperative adjuvant therapy, perioperative immunotherapy, or maintenance therapy can be set up. This model has strong clinical mapping, but is technically complex, has longer cycles, and requires high consistency in postoperative care and local resection; it is not suitable for early large-scale screening, but is suitable when key candidate drugs enter translational validation.

Modeling and dosing timelines
First establish orthotopic tumor burden, and confirm enrollment by volume, IVIS, or local pathology. Premature resection may result in an insufficient relapse window, while delayed resection may affect animal status and postoperative observation. Local resection, debulking, or local treatment is performed according to the program. Postoperative recovery status, body weight, and general condition are recorded. Postoperative observation continues for 2–8 weeks or longer, recording local relapse, distant metastasis, survival, and immune changes.

Detection endpoints

MRD and relapse layer: Time to local relapse, relapse burden, IVIS, resection margin/residual lesion, local pathology, and survival

Distant metastasis layer: Lung metastasis, brain metastasis, lymph node metastasis, organ pathology, and survival

Immune layer: CD8/Treg, myeloid cells, memory T cells, PD-L1, IFN-γ, Granzyme B, and cytokines

Safety layer: Body weight, postoperative recovery, wound condition, major organ pathology, and treatment-related toxicity

Recommended positive controls
BRAF-mutant programs can set BRAF/MEK inhibitors as perioperative or postoperative maintenance references. In syngeneic orthotopic models, anti-PD-1, anti-CTLA-4, or PD-1/CTLA-4 combination can be set as postoperative immune maintenance references. STING agonists, oncolytic viruses, or local cytokines can be set based on local relapse and MRD clearance questions.

How to Select the Right Model for Your Program?

By Molecular Subtype

By Drug Type

By Research Objective

By Route of Administration

By Development Pathway

  • BRAF-mutant programs: Prioritize A375, SK-MEL-28, Colo829, or WM793. For BRAF/MEK combination, PROTAC, or resistance reversal programs, add long-term dosing, resistant derivatives, or withdrawal rechallenge designs.
  • NRAS/NF1 programs: Consider SK-MEL-2, SK-MEL-30, or WM1366. Prioritize alignment between molecular background and mechanism; do not substitute with BRAF-mutant models.
  • High-invasion and metastasis programs: For high-invasion, lung metastasis, brain metastasis, and local relapse programs, prioritize A2058, WM266-4, B16-F10, or organ-derived lines. For brain metastasis, use brain metastasis-related models for validation.
  • Uveal melanoma programs: Prioritize liver metastasis and GNAQ/GNA11-related models. Do not directly apply the cutaneous melanoma BRAF pathway.
  • BRAF/MEK targeted agents: Start with BRAF-mutant subcutaneous CDX, then escalate to orthotopic, lung metastasis, or brain metastasis models. For resistance programs, add long-term dosing, relapse, and pathway recovery assessments.
  • MEK/ERK/PI3K combination strategies: For NRAS/NF1 background programs, use molecularly matched models and focus on pERK, pAKT, cell cycle, and resistance bypass.
  • Immune checkpoint and combination immunotherapy: PD-1, PD-L1, CTLA-4, STING, oncolytic virus, and radiotherapy combination programs should prioritize syngeneic immunocompetent models. If the drug depends on the human immune system, use humanized models.
  • ADCs, bispecifics, and TCEs: For ADC and bispecific programs, select cell lines based on target expression stability. For TCE and CAR-T/NK programs, further consider humanized immune models and in vitro human immune killing linkage.
  • Brain metastasis therapeutics: For brain-penetrant small molecules, brain metastasis ADCs, immunotherapy combinations, or local therapy programs, use brain metastasis models with brain tissue exposure, MRI/BLI, survival, and brain pathology endpoints.
  • Uveal melanoma therapeutics: For uveal melanoma programs, select liver metastasis models and set positive references and endpoints based on GNAQ/GNA11, PKC, MEK, or liver-directed therapy mechanisms.
  • Rapid tumor shrinkage and dose finding: Prioritize subcutaneous CDX. Key endpoints include TGI, RTV, terminal tumor weight, plasma drug concentration, tumor tissue concentration, and target pathway changes.
  • Local invasion and lymphatic dissemination: Prioritize skin orthotopic models. Key endpoints include orthotopic burden, local invasion, lymph node metastasis, local pathology, and survival.
  • Lung metastasis: For lung colonization, select tail vein lung metastasis models; for the natural metastatic cascade, select orthotopic spontaneous lung metastasis or post-resection lung metastasis models.
  • Brain metastasis: Select left ventricle/carotid artery injection or intracranial inoculation based on the question. The former is better suited to brain colonization and BBB questions; the latter is better suited to intracranial efficacy and brain tissue exposure.
  • Immunotherapy: Prioritize B16-F10, YUMM1.7, or YUMMER1.7 syngeneic models. For human immune-dependent therapies, use humanized models.
  • Relapse and MRD clearance: Prioritize post-resection relapse observation in skin orthotopic models. Key endpoints include local relapse, lung/brain metastasis, time to relapse, survival, and immune infiltration.
  • Systemic administration: Oral, intraperitoneal, intravenous, and subcutaneous dosing are suitable for subcutaneous CDX, orthotopic, metastasis, and immune models. Set dosing frequency based on half-life, toxicity window, and model progression rate.
  • Local administration: Local injection, intratumoral dosing, skin local delivery, oncolytic virus, and local immune activation are better suited to orthotopic or syngeneic immune models. Evaluate local drug distribution and local immune response in parallel.
  • Brain metastasis administration: Brain metastasis programs should consider BBB penetration and brain tissue exposure. After systemic dosing, measure brain tissue drug concentration; intracranial models are better suited to evaluating local intracranial efficacy.
  • Combination immunotherapy dosing: Set dosing sequence based on mechanism, such as targeted debulking followed by immunotherapy, radiotherapy induction followed by immunotherapy, or local STING activation followed by checkpoint blockade.
  • BRAF-mutant pathway: BRAF-mutant subcutaneous CDX early screening → orthotopic model validation of local microenvironment → resistance/withdrawal models for long-term strategy → lung/brain metastasis models for deeper evaluation.
  • Immunotherapy pathway: Syngeneic subcutaneous early screening → syngeneic orthotopic validation of local immune microenvironment → lung/brain metastasis scenario validation → humanized model confirmation when needed.
  • Brain metastasis pathway: High-invasion CDX ranking → brain metastasis model validation of BBB and intracranial efficacy → MRI/BLI and brain tissue exposure linkage.
  • Uveal melanoma pathway: Basic efficacy model early screening → intraocular or liver metastasis-related model validation → liver metastasis model as the key organ scenario.

Why Alfa Cytology?

Driver-Driven & Subtype Modeling
Melanoma pathogenesis varies significantly across subtypes (cutaneous, acral, mucosal, and uveal). Alfa Cytology designs tailored model pathways based on core driver profiles (BRAF V600E, NRAS, NF1, c-KIT), avoiding broad generalizations across molecular variants.

Stratified Cell Line & Syngeneic Directory
Model selection determines immunotherapy and targeted therapy readouts. Alfa Cytology helps clients match robust systems—such as A375, SK-MEL-28, B16-F10, YUMM1.7, and YUMMER1.7—based on mutation status, immunogenicity, and metastatic potential.

Organ-Specific Metastasis Models
Subcutaneous models cannot answer questions related to spontaneous organ colonization. Alfa Cytology helps clients generate critical evidence through organ-specific metastasis models, including lung anti-colonization, blood-brain barrier (BBB) penetration for brain metastasis, and hepatic metastasis models for uveal melanoma.

Immunotherapy Validation & Integrated PK/PD
Programs targeting immune checkpoints (PD-1, CTLA-4, LAG-3), STING agonists, or combination regimens require immunocompetent profiling. Alfa Cytology configures syngeneic workflows, immune cell infiltration assays, and integrated PK/PD to track deep tumor regression and TME modulation.

Alfa Cytology is a global leader in melanoma translational research, delivering integrated animal model solutions that span molecular stratification, organ-specific metastasis, and immune microenvironment evaluation. If our services align with your program, please don't hesitate to contact us to learn how we can accelerate your melanoma drug development.

Reference

  1. Guo W, et al. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther. 2021;6(1):424.

For research use only.

Online Inquiry